Avior Wealth Management LLC Buys 7,658 Shares of Becton, Dickinson and Company $BDX

Avior Wealth Management LLC grew its position in Becton, Dickinson and Company (NYSE:BDX) by 2,934.1% in the second quarter, Holdings Channel reports. The fund owned 7,919 shares of the medical instruments supplier’s stock after acquiring an additional 7,658 shares during the quarter. Avior Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $1,364,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 3.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock worth $2,880,510,000 after acquiring an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after acquiring an additional 667,957 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Becton, Dickinson and Company by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock valued at $1,012,649,000 after acquiring an additional 312,124 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier’s stock worth $707,872,000 after purchasing an additional 37,733 shares during the period. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on BDX. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research report on Thursday. They set a “sector perform” rating and a $211.00 price objective for the company. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Barclays lowered their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a report on Tuesday, June 3rd. Finally, Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $213.09.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $184.59 on Monday. The firm has a 50 day moving average of $188.27 and a 200-day moving average of $188.49. The company has a market cap of $52.91 billion, a price-to-earnings ratio of 33.20, a price-to-earnings-growth ratio of 1.49 and a beta of 0.27. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock valued at $551,536 over the last ninety days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.